RxDoctor Payments Data

Adam Traill, DO

Hospitalist · Demorest, GANPI 1124112867

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,400 of the $2,753 with a category attached, or 87.2%. Roche Molecular Systems, Inc. accounts for 87.2% of it on its own, with 6 other manufacturers making up the rest. 2024 is the largest year on record at $2,400, 8.1 times the $298 reported in 2019. Among hospitalist clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,753in general payments, 2019–2025

Across 33 payments — averaging $83.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roche Molecular Systems, Inc.$2K
  • Pfizer$150
  • E.r. Squibb & Sons, L.L.C.$110
  • Johnson & Johnson$37
  • Irhythm Technologies, Inc.$22
  • Sunovion Pharmaceuticals Inc.$19
  • plus $15 from 1 others

What the payments were for

  • Speaking & faculty fees$2,40087%
  • Food & beverage$35313%

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,753 in reported general payments places this provider in the 95th percentile of 812 hospitalist providers in Georgia.

See all hospitalist providers in Georgia

Medicare billing

Part B allowed, 2024
$61,469
Medicare patients
223
Services billed
693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$13,650
Ranolazine ErRanolazine20$750
Pantoprazole Sodium38$415
Metoprolol Succinate49$351
Atorvastatin Calcium39$294
Levothyroxine Sodium26$251
Metoprolol Tartrate55$233
Potassium Chloride13$227
Gabapentin17$212
Nitroglycerin13$179
Losartan Potassium32$163
Cefdinir11$162
Digoxin14$153
Hydralazine Hcl19$151
Furosemide28$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$150$13,65022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 812 hospitalist providers in Georgia.

Other hospitalist in Demorest

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →